HummingbirdTM TTS

 Company Summary:
  • Preceptis Medical is a US based, privately-held pediatric ENT device company commercializing the HummingbirdTM TTS, a surgical technology to minimize trauma during ear tube placements in children allowing the use of moderate sedation outside the operating room.
Transaction Overview:
  • On 13 June, 2018, Preceptis Medical announced that it has closed its Series B financing led by a group of Chinese private investors with follow-on funding by Montesy Helen (HK) Limited.
  • In conjunction with the financing, Preceptis’ Chinese partners will be distributing the Hummingbird in mainland China and Hong Kong.
Significance of the Transaction:
  • The Series B financing allows the Company to expand its commercial infrastructure, complete its office indication study, and develop future pipeline services and technologies.
Healthios Role:
  • Healthios served as exclusive financial adviser to Preceptis Medical in its Series B financing, specifically in the US, European, and Asian markets, working in conjunction with a strategic advisor in mainland China.
  • This transaction highlights Healthios commitment to capital formation worldwide and success in working with a number of resources in our client’s best interest to secure funds needed to drive value along the emerging growth continuum.